Skip to content
July 11, 2023

Crossbow Therapeutics Launches with $80 Million Series A Financing to Advance a Novel Class of Antibody Therapies to Treat Cancer

You are about to leave MPM BioImpact's website. MPM BioImpact is not responsible for the content on other companies' websites.

Cancel Continue